“Snurf” Abuse Reports Revive Interest In DXM Bills
This article was originally published in The Tan Sheet
Executive Summary
A recent report of young people suspected of abusing "Snurf" has reignited interest on Capitol Hill in restricting bulk purchases of raw dextromethorphan and an age restriction on OTCs containing the cough suppressant
You may also be interested in...
FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement
A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare
Advisory Committee On Dextromethorphan Raises Stakes On Age Restriction
The Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare
More industry-friendly DXM bill introduced
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, introduce the Dextromethorphan Abuse Reduction Act June 25 to set an age limit on purchases of the OTC products containing the ingredient. S. 1383, which was referred to the Judiciary Committee, would ban retail sales of DXM OTC products to consumers under 18 years. The legislation differs from a DXM bill then-Sen. Joe Biden introduced in the previous Congress, the Consumer Healthcare Products Association says (1"The Tan Sheet" Sept. 15, 2008). In a change CHPA lobbied for, S. 1383 does not require adding raw DXM to the Controlled Substances Act, the trade group said June 26. Classifying raw DXM as a controlled substance would unnecessarily increase drug firms' regulatory burdens and is not needed to curb abuse of the cough medicine ingredient, according to CHPA